BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 27305819)

  • 1. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
    Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
    J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer.
    Gu Y; Li J; Li Y; Song L; Li D; Peng L; Wan Y; Hua S
    Int J Nanomedicine; 2016; 11():5757-5770. PubMed ID: 27843316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles.
    Wang J; Ma W; Tu P
    Macromol Biosci; 2015 Sep; 15(9):1252-61. PubMed ID: 25981672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zwitterionic Polymer Micelles with Dual Conjugation of Doxorubicin and Curcumin: Synergistically Enhanced Efficacy against Multidrug-Resistant Tumor Cells.
    Zhao G; Sun Y; Dong X
    Langmuir; 2020 Mar; 36(9):2383-2395. PubMed ID: 32036662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
    Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
    Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of A-B-C-type amphiphilic copolymer on reversal of drug resistance in MCF-7/ADR breast carcinoma.
    Zhang L; Lu J; Qiu L
    Int J Nanomedicine; 2016; 11():5205-5220. PubMed ID: 27785023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth.
    Zhang D; Xu Q; Wang N; Yang Y; Liu J; Yu G; Yang X; Xu H; Wang H
    Int J Nanomedicine; 2018; 13():4549-4561. PubMed ID: 30127606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
    Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
    Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a novel biocompatible magnetic nanomedicine based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast cancer.
    Rastegar R; Akbari Javar H; Khoobi M; Dehghan Kelishadi P; Hossein Yousefi G; Doosti M; Hossien Ghahremani M; Shariftabrizi A; Imanparast F; Gholibeglu E; Gholami M
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):207-216. PubMed ID: 29688063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-assembly of doxorubicin and curcumin targeted micelles for synergistic delivery and improving anti-tumor efficacy.
    Ma W; Guo Q; Li Y; Wang X; Wang J; Tu P
    Eur J Pharm Biopharm; 2017 Mar; 112():209-223. PubMed ID: 27913127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming multidrug resistance by intracellular drug release and inhibiting p-glycoprotein efflux in breast cancer.
    Mao J; Qiu L; Ge L; Zhou J; Ji Q; Yang Y; Long M; Wang D; Teng L; Chen J
    Biomed Pharmacother; 2021 Feb; 134():111108. PubMed ID: 33341670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
    Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
    Cui T; Zhang S; Sun H
    Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer.
    Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G
    Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a folate-modified curcumin loaded micelle delivery system for cancer targeting.
    Yang C; Chen H; Zhao J; Pang X; Xi Y; Zhai G
    Colloids Surf B Biointerfaces; 2014 Sep; 121():206-13. PubMed ID: 24984268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
    Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
    J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
    Lee ES; Na K; Bae YH
    J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
    Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
    Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctionalized Micelles Facilitate Intracellular Doxorubicin Delivery for Reversing Multidrug Resistance of Breast Cancer.
    Cao A; Ma P; Yang T; Lan Y; Yu S; Liu L; Sun Y; Liu Y
    Mol Pharm; 2019 Jun; 16(6):2502-2510. PubMed ID: 30998372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.